Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin vs Observation in DLBCL Remission
NCT00322218Phase 3Terminated
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- May 2006
- Primary completion
- Dec 2008
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of ibritumomab tiuxetan in diffuse large B-cell lymphoma (DLBCL), sponsored by Spectrum Pharmaceuticals, Inc.. Started May 2006; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00322218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322218.